{"registerEntryDetail":{"account":{"firstPublicationDate":"2022-03-07T13:31:20.000Z","registerNumber":"R003051"},"activity":{"code":"ACT_ORGANIZATION","de":"Unternehmen","en":"Company"},"activityDescription":"Alexion, AstraZeneca Rare Disease ist der Unternehmensbereich von AstraZeneca, der sich auf seltene Krankheiten konzentriert und durch die Übernahme von Alexion Pharmaceuticals, Inc. im Jahr 2021 entstand. Ziel von Alexion ist es, Patienten und Familien, die von schwerwiegenden seltenen Krankheiten oder lebensbedrohlichen Blutungen betroffen sind, durch die Entdeckung, Entwicklung und Verbreitung lebensverändernder Therapien zu helfen. Alexion konzentriert seine Forschungsaktivitäten auf neuartige Moleküle und Ziele in der Komplement-Kaskade und seine Entwicklungsaktivitäten auf die therapeutischen Kernbereiche Hämatologie, Nephrologie, Neurologie, Stoffwechselstörungen und Kardiologie. Alexion hat seinen Hauptsitz in Boston, Massachusetts/USA, die deutsche Zentrale ist in München (Alexion Pharma Germany GmbH).\r\n\r\nAlexion begleitet in Deutschland legislative und politische Initiativen und steht als kompetenter Dialogpartner zur Verfügung.","activityOperationType":"BOTH","clientOrganizations":[],"clientPersons":[],"codexViolation":false,"disclosureRequirementsExist":true,"donationInformationRequired":false,"donators":[],"employeeCount":{"from":1,"to":10},"fieldsOfInterest":[{"code":"FOI_BUNDESTAG","de":"Bundestag","en":"Bundestag"},{"code":"FOI_BUNDESTAG|FOI_BUNDESTAG_LEGAL","de":"Rechtsstellung der Abgeordneten","en":"Legal status of member of parliament"},{"code":"FOI_BUNDESTAG|FOI_BUNDESTAG_PARLIAMENTARY","de":"Parlamentarisches Verfahren","en":"Parliamentary procedure"},{"code":"FOI_ECONOMY","de":"Wirtschaft","en":"Economy"},{"code":"FOI_ECONOMY|FOI_ECONOMY_COMPETITION_LAW","de":"Wettbewerbsrecht","en":"Competition law"},{"code":"FOI_ECONOMY|FOI_ECONOMY_INDUSTRIAL","de":"Industriepolitik","en":"Industrial policy"},{"code":"FOI_ENERGY","de":"Energie","en":"Energy"},{"code":"FOI_ENERGY|FOI_ENERGY_OVERALL","de":"Allgemeine Energiepolitik","en":"Energy policy in general"},{"code":"FOI_ENVIRONMENT","de":"Umwelt","en":"Environment"},{"code":"FOI_ENVIRONMENT|FOI_ENVIRONMENT_CLIMATE","de":"Klimaschutz","en":"Climate protection"},{"code":"FOI_ENVIRONMENT|FOI_ENVIRONMENT_OTHER","de":"Sonstiges im Bereich „Umwelt“","en":"Other in the field of “Environment”"},{"code":"FOI_ENVIRONMENT|FOI_ENVIRONMENT_SUSTAINABILITY","de":"Nachhaltigkeit und Ressourcenschutz","en":"Sustainability and resource protection"},{"code":"FOI_EUROPEAN_UNION|FOI_EU_DOMESTIC_MARKET","de":"EU-Binnenmarkt","en":"EU internal market"},{"code":"FOI_EUROPEAN_UNION|FOI_EU_LAWS","de":"EU-Gesetzgebung","en":"EU legislation"},{"code":"FOI_EUROPEAN_UNION|FOI_EU_POLITICS","de":"Institutionelle Fragen der EU","en":"Institutional questions of European politics"},{"code":"FOI_EUROPEAN_UNION","de":"Europapolitik und Europäische Union","en":"European politics and the EU"},{"code":"FOI_FOREIGN_TRADE","de":"Außenwirtschaft","en":"Foreign trade"},{"code":"FOI_HEALTH","de":"Gesundheit","en":"Health"},{"code":"FOI_HEALTH|FOI_HEALTH_CARE","de":"Pflege","en":"Health care"},{"code":"FOI_HEALTH|FOI_HEALTH_MEDICINE","de":"Arzneimittel","en":"Medicine"},{"code":"FOI_HEALTH|FOI_HEALTH_OTHER","de":"Sonstiges im Bereich „Gesundheit“","en":"Other in the field of “Health”"},{"code":"FOI_HEALTH|FOI_HEALTH_PROMOTION","de":"Gesundheitsförderung","en":"Health promotion"},{"code":"FOI_HEALTH|FOI_HEALTH_SUPPLY","de":"Gesundheitsversorgung","en":"Health supply"},{"code":"FOI_LAW","de":"Recht","en":"Law"},{"code":"FOI_LAW|FOI_LAW_CIVIL_RIGHT","de":"Zivilrecht","en":"Civil rights"},{"code":"FOI_LAW|FOI_LAW_CRIMINAL","de":"Strafrecht","en":"Criminal law"},{"code":"FOI_LAW|FOI_LAW_LEGAL","de":"Rechtspolitik","en":"Legal policy"},{"code":"FOI_LAW|FOI_LAW_OTHER","de":"Sonstiges im Bereich „Recht“","en":"Other in the field of “Law”"},{"code":"FOI_LAW|FOI_LAW_PUBLIC","de":"Öffentliches Recht","en":"Public law"},{"code":"FOI_MEDIA","de":"Medien, Kommunikation und Informationstechnik","en":"Media, communication and information technology"},{"code":"FOI_MEDIA|FOI_MEDIA_ADVERTISEMENT","de":"Werbung","en":"Advertising"},{"code":"FOI_MEDIA|FOI_MEDIA_DIGITALIZATION","de":"Digitalisierung","en":"Digitalization"},{"code":"FOI_MEDIA|FOI_MEDIA_PRIVACY","de":"Datenschutz und Informationssicherheit","en":"Data protection and information security"},{"code":"FOI_POLITICAL_PARTIES","de":"Politisches Leben, Parteien","en":"Political life, parties"},{"code":"FOI_PUBLIC_FINANCE","de":"Öffentliche Finanzen, Steuern und Abgaben","en":"Public finances, taxes and duties"},{"code":"FOI_SCIENCE_RESEARCH_TECHNOLOGY","de":"Wissenschaft, Forschung und Technologie","en":"Science, research and technology"},{"code":"FOI_SOCIAL_POLICY","de":"Gesellschaftspolitik und soziale Gruppen","en":"Social politics and social groups"},{"code":"FOI_SOCIAL_SECURITY","de":"Soziale Sicherung","en":"Social security"},{"code":"FOI_SOCIAL_POLICY|FOI_SP_DIVERSITY","de":"Diversitätspolitik","en":"Diversity policy"},{"code":"FOI_SOCIAL_POLICY|FOI_SP_GENDER","de":"Geschlechterpolitik","en":"Gender politics"},{"code":"FOI_SOCIAL_SECURITY|FOI_SS_ACCIDENT","de":"Unfallversicherung","en":"Accident insurance"},{"code":"FOI_SOCIAL_SECURITY|FOI_SS_BASIC","de":"Grundsicherung","en":"Basic security"},{"code":"FOI_SOCIAL_SECURITY|FOI_SS_HEALTH","de":"Krankenversicherung","en":"Health insurance"},{"code":"FOI_WORK","de":"Arbeit und Beschäftigung","en":"Work and employment"},{"code":"FOI_WORK|FOI_WORK_POLICY","de":"Arbeitsmarkt","en":"Job market"},{"code":"FOI_WORK|FOI_WORK_RIGHT","de":"Arbeitsrecht/Arbeitsbedingungen","en":"Work right"}],"financialExpensesEuro":{"fiscalYearEnd":"12/21","fiscalYearStart":"01/21","from":470001,"to":480000},"id":3298,"legislativeProjects":[{"printingNumber":"20/198753"}],"lobbyistIdentity":{"address":{"city":"München","country":{"code":"DE"},"type":"NATIONAL"},"identity":"ORGANIZATION","legalForm":{"code":"LF_GMBH","code_de":"Gesellschaft mit beschränkter Haftung (GmbH)","code_en":"Limited liability company (GmbH)","type":"JURISTIC_PERSON"},"legalRepresentatives":[{"commonFirstName":"Graham","function":"Geschäftsführer","lastName":"Skarnvad ","organizationMemberEmails":["alexion.germany@alexion.com"],"phoneNumber":"+4989457091300"}],"membershipEntries":["AG Therapie Seltene Erkrankungen (ATSE)","Bundesverband der Pharmazeutischen Industrie e.V. (BPI)","BioM","Pharmainitiative Bayern","Pharma Fakten e.V. ","Unternehmen für München e.V.","Die Deutsche Gesellschaft für Muskelkranke (DGM) e.V.","AKG e.V."],"name":"Alexion Pharma Germany GmbH","namedEmployees":[{"commonFirstName":"Matthias","lastName":"Heck"},{"commonFirstName":"Matthias","lastName":"Ziegler"}],"organizationEmails":["alexion.germany@alexion.com"],"phoneNumber":"+4989457091300","websites":["www.alexion.de"]},"refuseDonationInformation":false,"refuseFinancialExpensesInformation":false,"refusePublicAllowanceInformation":false,"registerEntryMedia":[]},"registerNumber":"R003051","searchUrl":"https://www.lobbyregister.bundestag.de/suche/R003051/3298","source":"Deutscher Bundestag, Lobbyregister für die Interessenvertretung gegenüber dem Deutschen Bundestag und der Bundesregierung","sourceUrl":"https://www.lobbyregister.bundestag.de"}